You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 29, 2025

Rising Company Profile


✉ Email this page to a colleague

« Back to Dashboard


What is the competitive landscape for RISING

RISING has two hundred and ninety-four approved drugs.

There are three tentative approvals on RISING drugs.

Summary for Rising
US Patents:0
Tradenames:231
Ingredients:226
NDAs:294

Drugs and US Patents for Rising

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Rising ACETAZOLAMIDE acetazolamide CAPSULE, EXTENDED RELEASE;ORAL 203917-001 Jun 18, 2019 DISCN No No ⤷  Try for Free ⤷  Try for Free
Rising POTASSIUM CITRATE potassium citrate TABLET, EXTENDED RELEASE;ORAL 077440-001 Jun 9, 2006 AB RX No No ⤷  Try for Free ⤷  Try for Free
Rising ROPIVACAINE HYDROCHLORIDE ropivacaine hydrochloride SOLUTION;INJECTION 090318-004 Sep 23, 2014 DISCN No No ⤷  Try for Free ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 3 of 3 entries

Expired US Patents for Rising

ApplicantTradenameGeneric NameDosageNDAApproval DatePatent No.Patent Expiration
Rising ALFENTA alfentanil hydrochloride INJECTABLE;INJECTION 019353-001 Dec 29, 1986 4,167,574 ⤷  Try for Free
Rising SUFENTA PRESERVATIVE FREE sufentanil citrate INJECTABLE;INJECTION 019050-001 May 4, 1984 3,998,834 ⤷  Try for Free
Rising SULFAMYLON mafenide acetate CREAM;TOPICAL 016763-001 Approved Prior to Jan 1, 1982 3,497,599 ⤷  Try for Free
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>Patent No.>Patent Expiration
Showing 1 to 3 of 3 entries
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Rising Market Position, Strengths & Strategic Insights

Last updated: July 27, 2025

Introduction

The global pharmaceutical industry stands at a pivot point characterized by rapid innovation, evolving consumer demands, and heightened regulatory scrutiny. As market dynamics shift, especially in areas like biologics, specialty drugs, and personalized medicine, understanding the competitive landscape becomes crucial for industry stakeholders. This analysis explores the rising players gaining market share, evaluates their core strengths, and uncovers strategic insights essential for informed decision-making.

Market Overview

The pharmaceutical sector experienced a robust CAGR over the past decade, with estimates projecting consistent growth driven by unmet medical needs, aging populations, and technological advances. Notably, emerging markets, such as China and India, have bolstered global supply chains, while high-income regions continue to focus on innovative therapies. The industry’s competitive structure is increasingly fragmented, with both established pharmaceutical giants and agile biotech startups intensifying their market pursuits.

Rising Market Position: Key Contenders

1. Biotech Innovators and Specialty Drug Firms

Biotech firms like Moderna, BioNTech, and Regeneron have risen sharply, propelled by breakthroughs in mRNA technology and targeted biologics. For instance, Moderna’s COVID-19 vaccine catapulted it onto the global stage, translating scientific innovation into commercial dominance. These companies leverage cutting-edge research, rapid development cycles, and strategic partnerships to capture market share.

2. Diversified Pharma Conglomerates

Major players such as Novartis, Roche, and Johnson & Johnson continue to expand their portfolios through acquisitions and alliances, especially in oncology, immunology, and rare diseases. Their diversified pipelines mitigate risks associated with patent expirations and market saturation.

3. Digital & AI-Driven Entities

New entrants employing artificial intelligence (AI) for drug discovery, clinical development, and supply chain optimization are gaining visibility. Companies like Atomwise and Exscientia utilize AI to reduce R&D timelines and costs, positioning themselves as disruptive forces in the industry.

4. Non-Traditional and Contract Manufacturing Organizations

CDMOs like Samsung Biologics and Lonza are transitioning from manufacturing service providers to strategic partners for R&D, thus acquiring increased market influence. Their scale and technological capabilities foster a competitive edge in biologics production.

Core Strengths of Rising Entities

Innovative R&D Capabilities

Emerging firms invest heavily in cutting-edge science, with a focus on personalized medicine and gene therapies. Their agility allows rapid adaptation to scientific advancements, leading to a high rate of pipeline progression.

Strategic Collaborations and Licensing Agreements

Partnerships with academia, tech companies, and larger pharma entities accelerate development and commercialization. For example, Moderna’s collaboration with Merck expanded its vaccine and oncology portfolio.

Regulatory Savvy and Market Access Strategies

Aggressive navigation of regulatory pathways and market-specific approaches enable quicker approval cycles and market penetration. Fast-track designations, emergency use authorizations, and regional strategies underpin their growth.

Manufacturing and Supply Chain Flexibility

Investment in flexible manufacturing platforms and robust supply chains ensures scalability and responsiveness. This resilience has been especially critical during the COVID-19 pandemic.

Digital Transformation and Data Analytics

Leveraging big data, AI, and machine learning enhances drug discovery success rates and personalized treatment options. Digital innovation also optimizes clinical trials and real-world evidence collection.

Strategic Insights for Industry Stakeholders

1. Embrace External Innovation through Collaborations

Established pharmaceutical companies should deepen strategic alliances with biotech startups and tech firms to access novel technologies and accelerate pipeline development.

2. Focus on Niche and Orphan Diseases

Targeting rare and underserved markets offers higher exclusivity periods and reduces competitive pressures. Companies like Axis Capital and Sarepta exemplify this strategy.

3. Invest in Digital and AI-driven Capabilities

Adopting advanced data analytics and AI tools can streamline R&D, improve clinical trial efficiency, and enhance personalized treatment strategies.

4. Optimize Supply Chain and Manufacturing Flexibility

Building resilient and scalable supply chains minimizes disruptions and enables rapid market response amid geopolitical and logistical challenges.

5. Navigate Regulatory Landscapes Strategically

Proactively engaging with regulators, leveraging expedited pathways, and understanding region-specific requirements accelerate drug approvals and market entry.

6. Focus on Patient-Centric and Digital Therapeutics

The shift toward digital health solutions and patient engagement platforms creates new revenue streams and enhances drug adherence, ultimately fortifying market position.

Conclusion

The pharmaceutical landscape continues to evolve at a breakneck pace. Rising players—driven by innovation, agility, and strategic collaborations—are reshaping market power dynamics. Traditional pharmas must adapt by embracing digital transformation, fostering external partnerships, and strategically targeting niche markets. Success hinges on agility, technological integration, and a patient-focused approach.

Key Takeaways

  • Innovation Drive: Biotech firms and digital innovators are rapidly expanding their market footprint through breakthroughs in personalized medicine and AI-enabled drug discovery.
  • Collaborative Edge: Strategic alliances with academia, tech firms, and larger pharma companies accelerate development timelines and market access.
  • Regulatory & Market Strategy: Navigating regulatory pathways efficiently with regional customization provides competitive advantage.
  • Supply Chain Resilience: Flexible manufacturing capabilities and robust supply chains mitigate risks and ensure continuity.
  • Digital Adoption: Leveraging big data and AI enhances R&D efficiency, reduces costs, and fosters personalized therapeutics.

FAQs

Q1: How are biotech companies disrupting traditional pharmaceutical markets?
A1: By introducing innovative therapies such as mRNA platforms and gene editing, biotech firms accelerate R&D processes, target niche markets like rare diseases, and often achieve first-mover advantages with novel treatments.

Q2: What strategic moves are leading pharmaceutical companies adopting to stay competitive?
A2: They are pursuing acquisitions of biotech startups, expanding pipeline portfolios, investing in digital transformation, and enhancing supply chain resilience.

Q3: How significant is digital transformation in pharmaceutical R&D?
A3: It is crucial, enabling faster drug discovery, predictive modeling, personalized medicine, and streamlining clinical trials, which collectively reduce costs and time-to-market.

Q4: Which emerging markets pose opportunities for pharmaceutical growth?
A4: China and India offer growing markets with expanding healthcare infrastructure, and they are becoming hubs for biologics manufacturing and local innovation.

Q5: How can regulatory strategies impact a company's market position?
A5: Proficiency in navigating expedited pathways and regional approvals accelerates market entry, enhances revenue potential, and creates barriers for slower competitors.


References:

  1. Deloitte Insights, 2022. "Global Pharmaceutical Industry Outlook."
  2. IQVIA, 2022. "The Future of Pharma Innovation."
  3. McKinsey & Company, 2023. "Navigating Regulatory Pathways in Pharma."
  4. BioWorld, 2022. "Emerging Biotech Leaders and Market Impact."
  5. Statista, 2023. "Global Pharmaceutical Market Revenue Forecasts."

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.